{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021674","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.667386+00:00","generated_at":"2026-06-02T11:39:56.336275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zai Lab Q1 product revenue $87.1M (+39% YoY); net loss $53.5M, VYVGART sales $13.2M","bullets":["Product revenue $87.1M (+39% YoY; +43% at CER); ZEJULA $45.5M (+7%), VYVGART $13.2M (launch Sep 2023).","Net loss $53.5M ($0.55 loss per ADS) vs $49.1M in Q1 2023; R&D $54.6M, SG&A $69.2M.","Cash $750.8M at Mar 31, 2024, down from $806.5M at Dec 31, 2023.","Appointed Andrew Zhu as Chief Commercial Officer for Greater China in April 2024.","Regulatory milestones: sBLA submitted for efgartigimod SC in CIDP; potential NMPA approvals for repotrectinib, sulbactam-durlobactam, efgartigimod SC in gMG in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021674","json":"https://secwatch.observer/filing/0001628280-24-021674.json","markdown":"https://secwatch.observer/filing/0001628280-24-021674.md","text":"https://secwatch.observer/filing/0001628280-24-021674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/0001628280-24-021674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/zlab-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:39:56.336275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec63e75ade4f77876502adf2efcd83c997bb9068","claim":"Zai Lab Ltd reported the first quarter of 2024 results: revenue $87.1 million, net income $53.5 million, EPS loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.55).","evidence_excerpt":"by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) sales of $13.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/0001628280-24-021674-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"$87.1 million"},{"label":"Net income","value":"$53.5 million"},{"label":"EPS","value":"loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.55)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}